A recent report from the medical journal Journal of Allergy and Clinical Immunology (JACI) suggests that researchers from Birmingham University in the UK have determined that e-cigarette addiction can have negative effects on the immune system.
Researchers from the University of Birmingham have found that the aerosol from e-cigarettes decreases the activity of immune cells involved in infection resistance, based on their study of blood samples taken from volunteers who had never used conventional cigarettes or e-cigarettes.
A research team conducted a study by exposing immune cells extracted from volunteers' blood to the vapor from e-cigarette liquids, in an attempt to simulate the conditions of regular e-cigarette inhalation by humans. Half of the participants were exposed to the vapor containing nicotine e-liquid, while the other half were exposed to the vapor containing nicotine-free e-liquid.
Although all immune cells have survived, their vitality has significantly declined. Researchers have discovered that this reduced vitality is due to an increase in levels of F-proteins within the cells, responsible for altering the shape of immune cells. By changing shape, these immune cells are unable to move effectively, thus compromising their protective functions. Furthermore, the study also revealed that even nicotine-free e-liquid generates the same effects on immune cells.
Previous studies have confirmed that e-cigarettes have negative effects on lung and heart function.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
